FMS-LIKE TYROSINE KINASE (FLT3) GENE ITD MUTATION IN ACUTE MYELOID LEUKEMIA

  • Rajko Kusec Institute of Clinical Chemistry Merkur University Hospital Zagreb Croatia in Department of Medicine Hematology Merkur University Hospital Zagreb Croatia
  • Maruska Marusic Vrsalovic Institute of Clinical Chemistry Merkur University Hospital Zagreb Croatia
  • Tanja Vranic Bobetic Institute of Clinical Chemistry Merkur University Hospital Zagreb Croatia
  • Slobodanka Ostojic Department of Medicine Hematology Merkur University Hospital Zagreb Croatia
  • Hrvoje Mingo Department of Medicine Hematology Merkur University Hospital Zagreb Croatia
  • Branimir Jaksic Department of Medicine Hematology Merkur University Hospital Zagreb Croatia
Keywords: FLT3 gene, leukemia, internal tandem duplication, prognostics, cytogenetics

Abstract

Background. FLT3 is a class III receptor tyrosine kinase expressed in normal stem cells and blasts of myeloid leukemia. Internal tandem duplication (ITD) of the FLT3 gene affecting the exons 14 and 15 leads to ligand-independent FLT3 dimerization and constitutive activation. This stimulates proliferation and induces inhibition of apoptosis which contributes to leukemogenesis. We have screened a panel of acute myeloid leukemia (AML) patients for the occurrence of FLT3/ITD mutation and correlated this mutation to patients’ survival and basic hematological parameters.

Methods. RT-PCR for ITD in exons 14 and 15 of FLT3 gene was done on bone marrow samples of 67 AML patients at diagnosis.

Results. There was a 16.4% incidence of FLT3/ITD mutation in the cohort of examined patients. By cytognetic subgroups there were 2/6 t(15;17) and 1 of 4 t(8;21) positive patients. The rest had normal and 2 had complex karyotype. Majority were of FAB M2 or M4 phenotype. For a subset of patients taken into comparative survival analysis there was a clear disadvantage for FLT3/ITD patients. No difference was found for basic hematological parameters between two groups.

Conclusions. As it is evident today that FLT3/ITD is the single most common genetic abnormality in AML that also presents unfavorable clinical prognostic marker, it should be included in molecular diagnostic testing of acute myeloid leukemia.

Downloads

Download data is not yet available.

References

Turner AM, Lin NL, Issarachai S, Lyman SD, Broudy VC. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 1996; 88: 3383–90.

Nakao M, Yokota S, Iwai T, Kaneko H,Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10:1911–8.

Moreno I, Martin G, Bolufer P, Barragan E, Rueda E, Roman J et al. Incidence and prognostic value of FLT3/ITD and D835 mutation in acute myeloid leukemia. Haematologica 2003; 88:19–24.

Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of FLT3 ITD in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the UK MRC AML10 and 12 trials. Blood 2001; 98:1752–9.

Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia 2003;17:1738– 52.

Iwai T, Taki T, Zang HW, Hanada R, Hongo T, Ohnishi H et al. Tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children’s cancer and leukemia. Study Group, Japan. Leukemia 1999; 13: 38–43.

Sheikhha MH, Awan A, Tobal K, Liu Yin JA. Prognostic significance of LFT3/ ITD and D835 mutations in AML patients. Hematology J 2003; 4:41–6.

How to Cite
1.
Kusec R, Marusic Vrsalovic M, Vranic Bobetic T, Ostojic S, Mingo H, Jaksic B. FMS-LIKE TYROSINE KINASE (FLT3) GENE ITD MUTATION IN ACUTE MYELOID LEUKEMIA. TEST ZdravVestn [Internet]. 1 [cited 5Aug.2024];73. Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/2413
Issue
Vol 73 (2004): Supplement I
Section
Professional Article


The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.

The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory

The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.

The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.

The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.